CytoCares

Home>CytoCares

CytoCares

CytoCares

CytoCares (Shanghai) Inc. is a global, immune-oncology focused biotech company dedicated on the research & development of first-in-class therapeutics for cancer treatment.

Mission Statement: Continuous Innovation for Life-Changing Therapies to People in Need and Benefit the People.

The company has developed several proprietary immuno-oncology therapeutic platforms, including TriTETM, CCNKTM, and CCMφTM. The pipeline antibodies developed based on these platforms could stimulate or modulate immune cells to fight against cancer.

CytoCares is a pioneer in utilizing of “Two-Signal” system of T cell activation in the multi-specific antibody design and has expanded its expertise from hematologic malignancies to solid tumor. CytoCares’ CCNKTM platform is designed to harness the immune functions of NK cells in cancer treatment. Specially, new antibody formats capable of stimulating the antitumor activity of innate immune cells are now in development in CytoCares with the ultimate goal of long-lasting tumor control. Antibodies generated from CCMφTM platform are designed to target macrophage using the TAM (tumor associated macrophage) reprogramming strategies.

CytoCares Team

Founder & Chairman

Huaxing Zhu, Ph.D

As the first batch of biopharmaceutical industrialization practitioners in China, Dr. Zhu has more than 20 years of industrial experience in genetically engineered protein and antibody technology.  Dr. Zhu has participated in the development of 4 genetically engineered drugs successively, and has undertaken the Innovation Fund of Ministry of Science and Technology and new drug creation projects for many times. Dr. Zhu, who received his Ph.D in genetics from Fudan University, is the founder of Suzhou Novoprotein Science and Technology Co., Ltd.  He is also the Industrial Mentor of Fudan Master Program, the Visiting Professor of Shanghai Jiaotong University, the Council Member of the Genetics Society of China, and the Council Member of Vaccine Society.

Founder & Chairman

Huaxing Zhu, Ph.D

As the first batch of biopharmaceutical industrialization practitioners in China, Dr. Zhu has more than 20 years of industrial experience in genetically engineered protein and antibody technology.  Dr. Zhu has participated in the development of 4 genetically engineered drugs successively, and has undertaken the Innovation Fund of Ministry of Science and Technology and new drug creation projects for many times.

Dr. Zhu, who received his Ph.D in genetics from Fudan University, is the founder of Suzhou Novoprotein Science and Technology Co., Ltd.  He is also the Industrial Mentor of Fudan Master Program, the Visiting Professor of Shanghai Jiaotong University, the Council Member of the Genetics Society of China, and the Council Member of Vaccine Society.

Co-Founder

Li Chen,Ph.D

PhD in biology from the Chinese University of Hong Kong. 20 years of direct experience with more than 10 different biologics in preclinical or clinical developments, including monoclonal antibodies, fc-fusion proteins, recombinant proteins, and pegylated proteins. Areas of expertise include biologics early discovery, preclinical and clinical developments, and regulatory affairs. Before joining CytoCares, Dr. Chen has served as senior scientist, Director of preclinical development, VP of R&D, and CTO in several biotech companies including CK Life Sciences (HK), Synermore Biologics (TW), and Bio-Cancer Treatment (BCT) Intl. Ltd.

Co-Founder

Li Chen,Ph.D

PhD in biology from the Chinese University of Hong Kong.

20 years of direct experience with more than 10 different biologics in preclinical or clinical developments, including monoclonal antibodies, fc-fusion proteins, recombinant proteins, and pegylated proteins.

Areas of expertise include biologics early discovery, preclinical and clinical developments, and regulatory affairs.

Before joining CytoCares, Dr. Chen has served as senior scientist, Director of preclinical development, VP of R&D, and CTO in several biotech companies including CK Life Sciences (HK), Synermore Biologics (TW), and Bio-Cancer Treatment (BCT) Intl. Ltd.

CEO

Yingfeng Huang

20-year experience of new drug research and development, presided over 10 therapeutic antibodies R&D, one of which was acquired by Merck Sereno and six projects entered clinical research stage. Over 15-year of pharmaceutical company management experience, and rich experience in building a marketing authorization holder (MAH) system. Before joining CytoCares, Mr.Huang has worked in Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. and Dragon Boat Biopharma as R&D director and general manager, and has rich experience in antibody R&D, technology platform construction, company operation and shareholder relationship maintenance.

CEO

Yingfeng Huang

20-year experience of new drug research and development, presided over 10 therapeutic antibodies R&D, one of which was acquired by Merck Sereno and six projects entered clinical research stage. Over 15-year of pharmaceutical company management experience, and rich experience in building a marketing authorization holder (MAH) system.

Before joining CytoCares, Mr.Huang has worked in Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. and Dragon Boat Biopharma as R&D director and general manager, and has rich experience in antibody R&D, technology platform construction, company operation and shareholder relationship maintenance.

COO

Zeng Li,Ph.D & CPA

Over 5-year experience of comprehensive operation management in biotech field, proficient in strategy making and business development, construction & optimization of business operation system, etc.  Over 10-year experience in PE & VC, familiar with investment in biotech, medical devices, IVD, and other healthcare and related fields, expert in business analysis & diagnosis.  Dr. Zeng received his Ph.D in genetics from Fudan University. He was an investment manager in Fosun Group, an Investment VP of Principle Capital, and a board director & vice general manager of of Genechem Co., Ltd.

COO

Zeng Li,Ph.D & CPA

Over 5-year experience of comprehensive operation management in biotech field, proficient in strategy making and business development, construction & optimization of business operation system, etc. 

Over 10-year experience in PE & VC, familiar with investment in biotech, medical devices, IVD, and other healthcare and related fields, expert in business analysis & diagnosis. 

Dr. Zeng received his Ph.D in genetics from Fudan University. He was an investment manager in Fosun Group, an Investment VP of Principle Capital, and a board director & vice general manager of of Genechem Co., Ltd.

VP,Research Head

Cathy Zhang,Ph.D

Over 14-years R&D working experience for drug development in target validation, pharmacodynamic evaluation, safety study, biological analysis, immunogenicity, assay development and validation, et al. Focused on preclinical stage of therapeutic antibody-drug discovery and cell therapy. Cathy Zhang Ph.D, Joint Ph.D training program between GSK (Shanghai) R&D Center and Kunming Medical University. Once worked for GSK, Hansoh Pharma, WuXi Biologics, and Harbour BioMed and completed the preclinical development of more than 10 innovative R&D projects.

VP,Research Head

Cathy Zhang,Ph.D

Over 14-years R&D working experience for drug development in target validation, pharmacodynamic evaluation, safety study, biological analysis, immunogenicity, assay development and validation, et al. Focused on preclinical stage of therapeutic antibody-drug discovery and cell therapy.

Cathy Zhang Ph.D, Joint Ph.D training program between GSK (Shanghai) R&D Center and Kunming Medical University. Once worked for GSK, Hansoh Pharma, WuXi Biologics, and Harbour BioMed and completed the preclinical development of more than 10 innovative R&D projects.

荣誉资质和政府项目支持

获2022年上海市创新型中小企业资质认定(2023年)
获2022年度上海市专精特新中小企业认定(2023年)
获浦东新区小微企业自主创新能力提升专项基金支持(2022年)
获上海市科技型中小企业技术创新资金计划支持(2022年)
获张江科学城专项发展资金支持(2021年)
获浦东新区小微企业自主创新能力提升专项基金支持(2021年)
获山东省抗体药物创新创业共同体重大科技项目支持(2021年)
获上海市科委科技型中小企业技术创新资金支持(2020年)
CC312项目获批国家卫健委“重大新药创制科技重大专项”支持(2019年)
获第六届中国创新创业大赛优秀奖(2018年)
获上海市科技创新行动计划生物医药科技支撑专项(2017年)

Partners

No One Fights Alone

CytoCares Technology Platform Pipeline Contact Us